New post from Savov I completely missed. Feb 12th:
To the Shareholders of Immunotech Laboratories Inc (IMMB) and the Partners of Immunotech Laboratories BG Dear shareholders, The medicinal products on the basis of the IPF platform – ITV-1, ITV-2, ITV-3, ITV-4, ITV-5 with US Patents ? 7,479,538, ? 7,625,565, ? 8,066,982, ? 8,067,531, ? 8,309,072 and the exclusive rights over the production and distribution with a notary signed in the US agreement are the property of Immunotech Laboratories BG until 2030. Every reference to these patents and the clinical trial of ITV-1 by Enzolytics Inc and International Medical Partners Ltd, as well as other entities, is a breach of the exclusive rights of Immunotech Laboratories BG, which is illegal and punishable by law. We have informed the management of Enzolytics and International Medical Partners, namely Charles Cotropia, Harry Zhabilov, Luchezar Ivanov, Volen Siderov that any reference to these patents on their side is illegal and made with the goal of misleading shareholders and investors, regarding which we will inform the competent court and the public. There will soon be a shareholder meeting of Immunotech Laboratories Inc (IMMB), because in his attempt to bankrupt the company, Harry Zhabilov who was formerly the CEO, resigned from all positions on November 12, 2019 without informing the shareholders. In this way, he left the company without management, which he hid from all shareholders. Zhabilov committed these actions in an attempt to illegally transfer all assets from Immunotech Laboratories Inc. to Enzolytics Inc., which has caused damages and lost profits to the shareholders of Immunotech Laboratories Inc. We will soon conduct a validation of the medicinal product ITV-1 with US Patent ? 7,479,538 and the estimated release on the market is until 09/30/2022. For additional information you can contact us on the electronic mail immunotechlabsbg@gmail.com or visit the website www.immunh.com Dimitar Savov President Immunotech Laboratories BG
